Conference Call with Gland Pharma Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Gland Pharma announced Q2FY25 results Financial Highlights: Consolidated revenue increased 2% YoY to Rs 14,058 million. Consolidated EBITDA decreased 8% YoY to Rs 2,961 million. Consolidated EBITDA margin was 21%, compared to 23% in Q2FY24. PAT Rs 1,635 million. Base business (excluding Cenexi) revenue grew 5% YoY to Rs 10,659 million. Base business (excluding Cenexi) EBITDA increased 5% YoY to Rs 3,645 million. Base business (excluding Cenexi) EBITDA margin was 34%, similar to Q2FY24. Other Highlights: R&D; expenses: Rs 493 million (4.6% of revenue). Regulatory filings: 7 ANDAs filed, 8 ANDAs approved in Q2FY25. Total filings: 363 ANDAs in the U.S. (304 approved, 59 pending). Global product registrations: 1,726. Capex: Total Capex incurred during the quarter ended September 30th, 2024, was Rs 1,037 million. US Market: Four molecules, including Cetrorelix Acetate, Ephedrine Sulfate, Tranexamic Acid, and Diazepam, were launched in the US market. China Market: Four of the nine products in the plan for China markets are currently under development, and five have received approvals. Complex Injectables: Nine filings completed in a targeted portfolio of 19 products. Six of these complex products have already been approved (6 launched), with three more expected to secure approval in due course. These products target an IQVIA market opportunity of $7.3 billion, reflecting the significant potential of this segment to drive future growth. Biologics: During the quarter, Gland entered into a binding term sheet with Dr. Reddy's Laboratories (DRL) to establish strategic cooperation for the biologics CDMO business. This partnership will leverage our state-of-the-art biologics manufacturing facility at Genome Valley in Hyderabad. We are very optimistic about this partnership's potential to create value for both organizations, and we expect to sign a definitive agreement shortly. Srinivas Sadu, Executive Chairman and CEO of Gland Pharma, said: “We had a good first half of 2025 and are on course to achieve our outcomes for the full year. This quarter, we reported Rs 14,058 million in revenue and Rs 2,961 million in EBITDA, representing a 21% EBITDA margin. Although our overall EBITDA margin was affected by Cenexi, our base business maintained a steady 34% EBITDA margin. Our core regulated markets, particularly the United States, continue to perform well. Our overall performance is in line with expectations. Looking ahead, we remain focused on our strategic priorities, which include entering new markets and building a solid foundation for future growth.” Result PDF